Pharmaceuticals News and Research

RSS

BioMarin commences GALNS Phase 3 trial in patients with Morquio A Syndrome

BioMarin Pharmaceutical announced today that it has initiated a pivotal Phase 3 trial for N-acetylgalactosamine 6-sulfatase, intended for the treatment of the lysosomal storage disorder Mucopolysaccharidosis Type IVA, also called Morquio A Syndrome.

1 Feb 2011

Genzyme's diagnostic products sold to Sekisui Chemical for $265 million

Genzyme Corporation today announced that it has completed the sale of its diagnostic products business to Sekisui Chemical Co., Ltd. for $265 million in cash.

1 Feb 2011

Savient announces pricing of $200 million 4.75% Convertible Senior Notes due 2018

Savient Pharmaceuticals, Inc. announced it has priced $200 million aggregate principal amount of 4.75% Convertible Senior Notes due 2018 (the "Notes") pursuant to an automatically effective registration statement filed with the Securities and Exchange Commission on January 31, 2011. In addition, Savient has granted the underwriters an option to purchase up to an additional $30 million aggregate principal amount of Notes, solely to cover over-allotments.

1 Feb 2011

Orexigen, Takeda announce FDA's issue of complete response letter for Contrave NDA

Orexigen® Therapeutics, Inc. and Takeda Pharmaceutical Company Limited announced today that the United States Food and Drug Administration (FDA) has issued a complete response letter dated January 31, 2011 regarding the New Drug Application for Contrave® (naltrexone HCl/bupropion HCl) extended-release tablets for the treatment of obesity, including weight loss and maintenance of weight loss.

1 Feb 2011

AVEO commences enrollment in tivozanib Phase 2 study in renal cell carcinoma

AVEO Pharmaceuticals, Inc. today announced that it has initiated patient enrollment in a multi-center Phase 2 exploratory biomarker study of tivozanib, its lead product candidate designed to optimally block the VEGF pathway by inhibiting all three VEGF receptors, in patients with renal cell carcinoma (RCC).

1 Feb 2011

Covidien first-quarter net sales increase 5% to $2.77 billion

Covidien plc today reported results for the first quarter of fiscal 2011 (October-December 2010). First-quarter net sales of $2.77 billion increased 5% from the $2.64 billion reported a year ago. Foreign exchange rate movement had no impact on the quarterly sales growth rate.

1 Feb 2011

PhRMA: 299 medicines under development for prevention and treatment of heart disease and stroke

An American dies of heart disease every 39 seconds, and African Americans suffer a higher death rate from heart disease and stroke than Americans overall. Partly as a result of having the highest prevalence of high blood pressure in the world, African Americans have a 1.5 times greater rate of heart disease death than other Americans and a 1.8 times greater rate of fatal stroke.

1 Feb 2011

AstraZeneca and Pfizer support Cancer Research UK in £5.5m Stratified Medicine programme

CANCER RESEARCH UK will be supported by AstraZeneca and Pfizer in a multimillion pound initiative to examine how genetic tests to improve cancer diagnosis can be best rolled out across the NHS.

1 Feb 2011

Circassia Phase II clinical trial confirms safety profile of ToleroMune cat allergy treatment

Circassia Ltd, a specialty biopharmaceutical company focused on allergy, today announced that the company's ToleroMune(R) cat allergy treatment significantly reduced patients' symptoms in a recently completed, large-scale phase II clinical trial. The study also confirmed the treatment's highly favourable safety profile.

1 Feb 2011

PCMA finds Ohio's Medicaid program can save $135 million over the next decade

Ohio's Medicaid program could cost taxpayers an additional $1.6 billion next year, a 49 percent jump in the state's share of costs for the health care program covering more than 2 million poor and disabled Ohioans, according to new information released by the Governor's Office of Health Transformation.

1 Feb 2011

French guy says Parkinson’s drug induced gambling and gay sex addiction, tries to sue GSK for $610,000

GlaxoSmithKline is being sued this week by a French father-of-two, alleging the British pharmaceutical firm’s drug – Reqip (Ropirnirole) to treat Parkinson’s disease turned him into a gay sex and gambling addict. Parkinson’s disease is a seriously and progressively debilitating disease that leads to tremors, slowing of movements and ultimately total immobility.

1 Feb 2011

Johnson & Johnson deal may bring HIV/AIDS drugs to developing countries faster

Johnson & Johnson's Tibotec Pharmaceuticals unit on Thursday announced it had granted multiple licenses to generic drug manufacturers "to provide copies of [the experimental HIV/AIDS drug rilpivirine hydrochloride] TMC278 in sub-Saharan Africa, India and parts of Asia if it's approved by regulators," Bloomberg Businessweek reports.

1 Feb 2011

Valeant announces binding agreement to acquire PharmaSwiss for euro 350 million

Valeant Pharmaceuticals International, Inc. and PharmaSwiss S.A. announced today that they have signed a binding agreement for Valeant to acquire PharmaSwiss, a privately-owned branded generics and over-the-counter pharmaceutical company based in Zug, Switzerland for euro 350 million.

1 Feb 2011

$FDA grants Onyx fast track designation for carfilzomib in treatment of relapsed and refractory multiple myeloma$

FDA grants Onyx fast track designation for carfilzomib in treatment of relapsed and refractory multiple myeloma

Onyx Pharmaceuticals, Inc. announced today that the U.S. Food and Drug Administration (FDA) has granted fast track designation for carfilzomib, a next generation proteasome inhibitor for the potential treatment of patients with relapsed and refractory multiple myeloma.

1 Feb 2011

AVANIR's NUEDEXTA for pseudobulbar affect now available by prescription

AVANIR Pharmaceuticals, Inc. today announced that NUEDEXTA™ (dextromethorphan hydrobromide and quinidine sulfate) is now available by prescription in the United States. NUEDEXTA is the first and only treatment approved by the U.S. Food and Drug Administration (FDA) for pseudobulbar affect (PBA).

1 Feb 2011

Parker Tennessee accepts to purchase common stock of King Pharmaceuticals at $14.25 per share

Pfizer Inc. today announced that its wholly-owned subsidiary, Parker Tennessee Corp., has accepted for purchase all of the shares validly tendered and not validly withdrawn pursuant to its tender offer for all outstanding shares of common stock of King Pharmaceuticals, Inc. at a purchase price of $14.25 per share, net to the seller in cash, without interest thereon and subject to any required withholding taxes.

1 Feb 2011

Oragenics to commence second phase 1 clinical trial for SMaRT Replacement Therapy

Florida-based biopharmaceutical company Oragenics, today announced its intention to commence a second phase 1 clinical trial of SMaRT Replacement Therapy.

31 Jan 2011

MAP Pharmaceuticals, Allergan collaborate for LEVADEX to treat acute migraine in adults

Allergan, and MAP Pharmaceuticals, today announced a collaboration within the United States for LEVADEX, a self-administered, orally inhaled therapy that has completed Phase III clinical development for the treatment of acute migraine in adults.

31 Jan 2011

Empire State Building, NYRR partner with MMRF for new myeloma drugs

For the first time in the 34-year history of the Empire State Building Run-Up, the New York Road Runners has partnered with a nonprofit as the event's Presenting Sponsor.

31 Jan 2011

Revolutions Medical: Major breakthrough in automatic retractable prefilled safety syringe technology

Revolutions Medical Corporation announces a major breakthrough in automatic retractable prefilled safety syringe technology. Building on the Company's proprietary vacuum based technology, important improvements in performance have been made that will set a new gold standard for safety in automatic prefilled syringes.

31 Jan 2011

Pharmaceuticals News and Research

BioMarin commences GALNS Phase 3 trial in patients with Morquio A Syndrome

Genzyme's diagnostic products sold to Sekisui Chemical for $265 million

Savient announces pricing of $200 million 4.75% Convertible Senior Notes due 2018

Orexigen, Takeda announce FDA's issue of complete response letter for Contrave NDA

AVEO commences enrollment in tivozanib Phase 2 study in renal cell carcinoma

Covidien first-quarter net sales increase 5% to $2.77 billion

PhRMA: 299 medicines under development for prevention and treatment of heart disease and stroke

AstraZeneca and Pfizer support Cancer Research UK in £5.5m Stratified Medicine programme

Circassia Phase II clinical trial confirms safety profile of ToleroMune cat allergy treatment

PCMA finds Ohio's Medicaid program can save $135 million over the next decade

French guy says Parkinson’s drug induced gambling and gay sex addiction, tries to sue GSK for $610,000

Johnson & Johnson deal may bring HIV/AIDS drugs to developing countries faster

Valeant announces binding agreement to acquire PharmaSwiss for euro 350 million

FDA grants Onyx fast track designation for carfilzomib in treatment of relapsed and refractory multiple myeloma

AVANIR's NUEDEXTA for pseudobulbar affect now available by prescription

Parker Tennessee accepts to purchase common stock of King Pharmaceuticals at $14.25 per share

Oragenics to commence second phase 1 clinical trial for SMaRT Replacement Therapy

MAP Pharmaceuticals, Allergan collaborate for LEVADEX to treat acute migraine in adults

Empire State Building, NYRR partner with MMRF for new myeloma drugs

Revolutions Medical: Major breakthrough in automatic retractable prefilled safety syringe technology

Event guide: World ADC Asia eBook

Latest eBooks

A practical guide to lipid nanoparticle formulation and resizing

Editorial Focus eBook - Spatial and single-cell omics (1st edition)

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Improving healthcare sustainability through carbon data

Managing vibration in IVF laboratories

A New Approach to Preventing Bladder Cancer Recurrence